HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ATL 227446

2'-O-(2-methoxyethyl)-modified phosphorothioate oligodeoxynucleotide with ability to suppress GH receptor mRNA in vitro

Also Known As:

ATL1103

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - ATL 227446: 2

Experts

1.	Aller, Javier: 1 article (08/2018)
2.	Atley, Lynne: 1 article (08/2018)
3.	Aylwin, Simon J B: 1 article (08/2018)
4.	Ayuk, John: 1 article (08/2018)
5.	Bidlingmaier, Martin: 1 article (08/2018)
6.	Brue, Thierry: 1 article (08/2018)
7.	Chanson, Philippe: 1 article (08/2018)
8.	Drake, William: 1 article (08/2018)
9.	Fajardo, Carmen: 1 article (08/2018)
10.	McCormack, Ann I: 1 article (08/2018)

Related Diseases

1.	Acromegaly 08/01/2018 - "This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. " 08/01/2018 - "This study provides proof of concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly." 08/01/2018 - "Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period. " 11/01/2016 - "octreotide in capsules, CAM2029, Somatoprim, ATL1103).Key words: acromegaly - cabergoline - new drugs - pegvisomant - somatostatin analogs - therapy."
2.	Injection Site Reaction 08/01/2018 - "ATL1103 was well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. "

Related Drugs and Biologics

1.	Insulin-Like Growth Factor I (IGF-1)
2.	Octreotide (Sandostatin)
3.	Somatostatin (Somatotropin Release-Inhibiting Factor)
4.	Cabergoline
5.	PTR 3173
6.	pegvisomant

Related Therapies and Procedures

1.	Therapeutics